|
Market Closed -
London S.E.
18:35:01 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.1000 GBX | 0.00% |
|
-9.09% | -60.78% |
| 10-22 | WINNERS & LOSERS: Camellia slumps on macadamia woe; Record climbs | AN |
| 10-20 | WINNERS & LOSERS: Ixico beats expectations; Shearwater wins deal | AN |
| Market Cap | 3.78M 5.06M 4.52M 4.18M 7.08M 481M 7.2M 50.25M 19.89M 252M 19M 18.59M 794M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.69M 4.93M 4.4M 4.07M 6.9M 468M 7.01M 48.95M 19.38M 245M 18.51M 18.11M 773M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 week | -9.09% | ||
| Current month | -31.03% | ||
| 1 month | -25.93% | ||
| 3 months | -41.18% | ||
| 6 months | -44.44% | ||
| Current year | -60.78% |
| 1 week | 0.09 |  | 0.13 |
| 1 month | 0.09 | | 0.16 |
| Current year | 0.09 | | 0.4 |
| 1 year | 0.09 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 01/07/2022 |
| Director/Board Member | 61 | 02/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 01/09/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/5/24 A | Free | Director | 22,000,000 | 2.6852% | ||
| 11/5/24 A | Free | Chairman | 22,000,000 | 2.6852% | ||
| 11/5/24 A | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -9.09% | -68.25% | -62.96% | 3.49M | |
| -2.54% | +1.31% | +55.10% | +120.84% | 1,135B | |
| -1.42% | +3.23% | +37.07% | +74.26% | 636B | |
| +0.16% | +0.08% | +25.14% | +97.36% | 505B | |
| -0.31% | +3.09% | +43.92% | +64.55% | 378B | |
| -1.34% | -0.47% | +66.63% | +40.56% | 358B | |
| -0.68% | +2.65% | +22.46% | +51.48% | 295B | |
| -1.20% | +3.04% | +2.62% | +26.97% | 266B | |
| -1.79% | +1.57% | +49.97% | +60.87% | 237B | |
| -0.73% | -0.10% | +29.24% | +101.19% | 193B | |
| Average | -0.60% | +1.04% | +26.39% | +57.51% | 400.43B | |
| Weighted average by Cap. | -0.26% | +2.66% | +40.99% | +82.13% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.87M -4.35M -4.02M -6.81M -462M -6.93M -48.35M -19.14M -242M -18.28M -17.89M -764M | -653K -873K -780K -720K -1.22M -82.86M -1.24M -8.67M -3.43M -43.42M -3.28M -3.21M -137M |
| Net Debt | -20.21K -27.03K -24.14K -22.3K -37.81K -2.57M -38.44K -268K -106K -1.34M -101K -99.3K -4.24M | -97.55K -130K -117K -108K -183K -12.39M -186K -1.3M -513K -6.49M -490K -479K -20.46M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | GBX 0.1000 | 0.00% | 12,521,143 |
| 22/10/26 | GBX 0.1000 | -9.09% | 13,902,970 |
| 21/10/26 | GBX 0.1100 | +10.00% | 12,136,802 |
| 20/10/26 | GBX 0.1000 | -11.11% | 39,967,311 |
| 19/10/26 | GBX 0.1125 | +2.27% | 42,402,258 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
